Roche firm on Genentech offer

Deal-watchers, take comfort. Roche says it's standing by its $43.7 billion offer to buy the rest of Genentech it doesn't own. Yes, there's been little activity on that deal lately, but Roche says it's still hungry for the buyout--and because Genentech shares have dropped below the $89 offer price, it might just decide to deal. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.